NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the pricing of its underwritten public offering of 20,325,204 shares of its common stock at a price to the public of $6.15 per share, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about February 6, 2017, subject to customary closing conditions.

Cantor Fitzgerald & Co. and Canaccord Genuity Inc. are joint book-running managers for the offering. H.C. Wainwright & Co., LLC is a co-manager for the offering.

Synergy intends to use the net proceeds from the offering to fund its commercialization activities related to TRULANCE™, further clinical development of plecanatide and for working capital and other general corporate purposes. Synergy may also use the net proceeds from this offering to fund possible acquisitions of other companies, products or technologies, though no such acquisitions are currently contemplated.

About Synergy Pharmaceuticals Inc.:

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. Synergy has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. Synergy discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform which includes one commercial product TRULANCE (plecanatide) and a second lead product candidate - dolcanatide